PROMINENT
Pemafibrate to reduce cardiovascular outcomes by reducing triglycerides in diabetic patients
- Stadium
- klaar
- Middel
- pemafibrate
- Populatie
- Diabetes Mellitus
- Fase
- III
- First Patient In
- 28 augustus 2017
- Last Patient In
- 20 maart 2020
- Last Patient Last Visit
- 18 juni 2022
National Lead
prof. dr. F.L.J. Visseren
Studiedirecteur
prof. dr. F.M.A.C. Martens
Cardioloog
Contact Kantoor
